MiRXES Secures $50 Million in Funding to Revolutionize Early Cancer Detection and Expand Global Reach

MiRXES, a pioneering biotechnology company based in Singapore, has successfully raised an impressive USD 50 million in funding, a significant milestone that underscores its commitment to transforming early cancer detection. Founded in 2014 as a spin-off from A*STAR’s Bioprocessing Technology Institute, MiRXES is on a mission to save lives through actionable and personalized diagnostics, particularly in the realm of cancer. The funds will be utilized to expand its robust pipeline of innovative diagnostic solutions, including the flagship GASTROClear test, which is celebrated as the world's first molecular blood test for early detection of gastric cancer, boasting an impressive detection rate of nearly 90% for Stage I and II cancers. This new capital will not only support the launch of early detection tests for colorectal and breast cancers this year, and for liver and ovarian cancers slated for 2024, but also bolster MiRXES's efforts in developing a precision oncology portfolio. This approach aims to provide comprehensive insights throughout the entire patient journey, ensuring timely and effective interventions. With operations in the USA, Japan, and China, coupled with a global sales and distribution network, MiRXES is well-positioned to lead the charge in early cancer detection across Southeast Asia and beyond. The successful funding round marks a pivotal step toward fulfilling their ambition of addressing unmet clinical needs not just in oncology, but also in other critical areas such as cardiovascular, metabolic, and infectious diseases. As MiRXES moves forward, it continues to stand at the forefront of biotechnology, driven by a steadfast commitment to innovation and patient care.